Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sophie Viaud

Showing results (11-20 of 22) with videos related to

Pageof 3
Sort By:
Cancer Research|December 15, 2010
Cyclophosphamide induces differentiation of Th17 cells in cancer patientsSophie Viaud, Caroline Flament, Mustapha Zoubir, et al.
Cell Cycle (Georgetown, Tex.)|January 5, 2011
An inhibitor of cyclin-dependent kinases suppresses TLR signaling and increases the susceptibility of cancer patients to herpesviridaeMustapha Zoubir, Caroline Flament, Abdelaziz Gdoura, et al.
Journal for Immunotherapy of Cancer|December 15, 2022
Human CD19-specific switchable CAR T-cells are efficacious as constitutively active CAR T-cells but cause less morbidity in a mouse model of human CD19<sup>+</sup> malignancyChristopher A Pennell, Heather Campbell, Meghan D Storlie, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|December 15, 2010
Updated technology to produce highly immunogenic dendritic cell-derived exosomes of clinical grade: a critical role of interferon-γSophie Viaud, Stéphanie Ploix, Valérie Lapierre, et al.
Journal of Leukocyte Biology|July 1, 2006
Dendritic cell derived-exosomes: biology and clinical implementationsNathalie Chaput, Caroline Flament, Sophie Viaud, et al.
Cancer Research|January 14, 2010
Opposing effects of toll-like receptor (TLR3) signaling in tumors can be therapeutically uncoupled to optimize the anticancer efficacy of TLR3 ligandsRosa Conforti, Yuting Ma, Yannis Morel, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 31, 2018
Switchable control over in vivo CAR T expansion, B cell depletion, and induction of memorySophie Viaud, Jennifer S Y Ma, Ian R Hardy, et al.
Cancer Research|July 5, 2011
IL-18 induces PD-1-dependent immunosuppression in cancerMagali Terme, Evelyn Ullrich, Laetitia Aymeric, et al.
Oncotarget|May 2, 2019
PD-L1 checkpoint blockade delivered by retroviral replicating vector confers anti-tumor efficacy in murine tumor modelsLeah A Mitchell, Kader Yagiz, Andrew Hofacre, et al.
Cancer Research|March 20, 2012
Cancer-induced immunosuppression: IL-18-elicited immunoablative NK cellsMagali Terme, Evelyn Ullrich, Laetitia Aymeric, et al.
Pageof 3

Showing results (11-20 of 22) with videos related to

Sort By:
Pageof 3
Cancer Research|December 15, 2010
Cyclophosphamide induces differentiation of Th17 cells in cancer patientsSophie Viaud, Caroline Flament, Mustapha Zoubir, et al.
Cell Cycle (Georgetown, Tex.)|January 5, 2011
An inhibitor of cyclin-dependent kinases suppresses TLR signaling and increases the susceptibility of cancer patients to herpesviridaeMustapha Zoubir, Caroline Flament, Abdelaziz Gdoura, et al.
Journal for Immunotherapy of Cancer|December 15, 2022
Human CD19-specific switchable CAR T-cells are efficacious as constitutively active CAR T-cells but cause less morbidity in a mouse model of human CD19<sup>+</sup> malignancyChristopher A Pennell, Heather Campbell, Meghan D Storlie, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|December 15, 2010
Updated technology to produce highly immunogenic dendritic cell-derived exosomes of clinical grade: a critical role of interferon-γSophie Viaud, Stéphanie Ploix, Valérie Lapierre, et al.
Journal of Leukocyte Biology|July 1, 2006
Dendritic cell derived-exosomes: biology and clinical implementationsNathalie Chaput, Caroline Flament, Sophie Viaud, et al.
Cancer Research|January 14, 2010
Opposing effects of toll-like receptor (TLR3) signaling in tumors can be therapeutically uncoupled to optimize the anticancer efficacy of TLR3 ligandsRosa Conforti, Yuting Ma, Yannis Morel, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 31, 2018
Switchable control over in vivo CAR T expansion, B cell depletion, and induction of memorySophie Viaud, Jennifer S Y Ma, Ian R Hardy, et al.
Cancer Research|July 5, 2011
IL-18 induces PD-1-dependent immunosuppression in cancerMagali Terme, Evelyn Ullrich, Laetitia Aymeric, et al.
Oncotarget|May 2, 2019
PD-L1 checkpoint blockade delivered by retroviral replicating vector confers anti-tumor efficacy in murine tumor modelsLeah A Mitchell, Kader Yagiz, Andrew Hofacre, et al.
Cancer Research|March 20, 2012
Cancer-induced immunosuppression: IL-18-elicited immunoablative NK cellsMagali Terme, Evelyn Ullrich, Laetitia Aymeric, et al.
Pageof 3